Y Mabs Therapeutics Stock Number Of Employees

YMAB Stock  USD 9.43  0.34  3.48%   
Y mAbs Therapeutics fundamentals help investors to digest information that contributes to Y MAbs' financial success or failures. It also enables traders to predict the movement of YMAB Stock. The fundamental analysis module provides a way to measure Y MAbs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Y MAbs stock.
Other Current LiabTotal Assets2.0M3.3M4.6M6.2M10.8M12.4M12.3M7.2M92.1M151.9M216.4M132.0M212.8M141.5M127.9M150.1M100%
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Y mAbs Therapeutics Company Number Of Employees Analysis

Y MAbs' Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.

Number of Employees

 = 

Full Time

+

Part Time

More About Number Of Employees | All Equity Analysis

Current Y MAbs Number Of Employees

    
  100  
Most of Y MAbs' fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Y mAbs Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

YMAB Number Of Employees Driver Correlations

Understanding the fundamental principles of building solid financial models for Y MAbs is extremely important. It helps to project a fair market value of YMAB Stock properly, considering its historical fundamentals such as Number Of Employees. Since Y MAbs' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Y MAbs' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Y MAbs' interrelated accounts and indicators.
1.00.99-0.96-0.710.870.780.850.821.00.89-0.270.870.830.750.850.590.420.34
1.01.0-0.98-0.660.830.760.80.761.00.86-0.250.890.860.710.830.530.360.28
0.991.0-0.96-0.680.810.80.830.780.990.88-0.280.880.840.740.830.530.420.31
-0.96-0.98-0.960.51-0.78-0.66-0.73-0.69-0.97-0.780.03-0.92-0.91-0.58-0.76-0.46-0.2-0.12
-0.71-0.66-0.680.51-0.82-0.82-0.92-0.94-0.68-0.90.61-0.39-0.3-0.95-0.76-0.76-0.86-0.81
0.870.830.81-0.78-0.820.660.860.940.850.85-0.20.650.590.750.810.730.490.53
0.780.760.8-0.66-0.820.660.880.790.760.93-0.530.460.390.840.630.540.770.6
0.850.80.83-0.73-0.920.860.880.970.820.96-0.330.610.530.920.820.710.760.62
0.820.760.78-0.69-0.940.940.790.970.790.93-0.330.550.480.90.830.830.70.63
1.01.00.99-0.97-0.680.850.760.820.790.87-0.240.880.850.720.840.560.380.3
0.890.860.88-0.78-0.90.850.930.960.930.87-0.430.620.550.930.810.70.70.59
-0.27-0.25-0.280.030.61-0.2-0.53-0.33-0.33-0.24-0.430.030.07-0.57-0.33-0.33-0.65-0.64
0.870.890.88-0.92-0.390.650.460.610.550.880.620.031.00.50.80.340.12-0.01
0.830.860.84-0.91-0.30.590.390.530.480.850.550.071.00.420.750.280.03-0.09
0.750.710.74-0.58-0.950.750.840.920.90.720.93-0.570.50.420.830.720.80.68
0.850.830.83-0.76-0.760.810.630.820.830.840.81-0.330.80.750.830.690.530.36
0.590.530.53-0.46-0.760.730.540.710.830.560.7-0.330.340.280.720.690.440.32
0.420.360.42-0.2-0.860.490.770.760.70.380.7-0.650.120.030.80.530.440.86
0.340.280.31-0.12-0.810.530.60.620.630.30.59-0.64-0.01-0.090.680.360.320.86
Click cells to compare fundamentals
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Competition

Based on the recorded statements, Y mAbs Therapeutics is currently employing 100 people. This is 99.09% lower than that of the Biotechnology sector and 81.32% lower than that of the Health Care industry. The number of employees for all United States stocks is 99.47% higher than that of the company.

YMAB Number Of Employees Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Y MAbs' direct or indirect competition against its Number Of Employees to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics of similar companies.
100.00490.00380.00375.00100%
Y MAbs is currently under evaluation in number of employees category among its peers.

Y MAbs ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Y MAbs' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Y MAbs' managers, analysts, and investors.
60.5%
Environmental
72.7%
Governance
67.5%
Social

YMAB Fundamentals

Return On Equity-0.25
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31-80%-60%-40%-20%
Return On Asset-0.12
Profit Margin(0.28) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31-80%-60%-40%-20%
Operating Margin(0.43) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31-80%-60%-40%-20%
Current Valuation355.31 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-310%100%200%300%
Shares Outstanding44.79 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31-10%0%10%20%30%
Shares Owned By Insiders12.21 %
Shares Owned By Institutions72.22 %
Number Of Shares Shorted3.84 M
Price To Book4.57 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31-80%-60%-40%-20%
Price To Sales5.12 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31-80%-60%-40%-20%
Revenue84.82 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31
Gross Profit57.7 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31
EBITDA(25.67 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31100%200%300%400%500%600%
Net Income(21.43 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31100%200%300%400%500%600%
Cash And Equivalents133.66 M
Cash Per Share3.06 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31200%400%600%800%1,000%
Total Debt1.42 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31-40%-20%0%20%40%60%80%
Debt To Equity0.02 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31100%200%300%400%500%600%
Current Ratio5.23 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-310%50%100%150%
Book Value Per Share2.06 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31200%400%600%800%1,000%1,200%1,400%
Cash Flow From Operations(27.23 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31200%400%600%800%
Short Ratio13.91 X
Earnings Per Share(0.54) X
Price To Earnings To Growth0.04 X
Target Price20.64
Number Of Employees100
Beta0.67
Market Capitalization432.74 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31-50%0%50%100%150%200%
Total Asset127.87 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31200%400%600%800%1,000%1,200%
Retained Earnings(457.47 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31500%1,000%1,500%2,000%
Working Capital90.98 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-31
Net Asset127.87 M

About Y MAbs Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Y mAbs Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y mAbs Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:
Check out Y MAbs Piotroski F Score and Y MAbs Altman Z Score analysis.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.54)
Revenue Per Share
1.921
Quarterly Revenue Growth
(0.1)
Return On Assets
(0.12)
Return On Equity
(0.25)
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.


 

Trending Assets

MRUS
Merus BV
42.83  1.38  3.33 
PCVX
Vaxcyte
87.72  -0.15  -0.17 
VECT
VectivBio Holding
16.85  0.00  0.00 
SNDX
Syndax Pharmaceuticals
13.93  0.46  3.41 
News Freq…Investor S…